Table 3.
Positivity for YB-1/p18 detection in human serum samples of patients with different malignant disorders
| n | YB-1/p18 positivity n/N (%) | |
|---|---|---|
|
All patients |
151 |
117/151 (77.5) |
| Male |
84 |
67/84 (79.8) |
| Female |
67 |
50/67 (74.6) |
|
Malignancy |
|
|
|
Group I: lung cancer |
37 |
32/37 (86.5) |
| Adeno |
15 |
12/15 (80) |
| Small cell |
10 |
9/10 (90) |
| Squamous |
10 |
9/10 (90) |
| Non small cell |
2 |
2/2 (100) |
|
Group II: breast cancer |
10 |
7/10 (70) |
| Ductal |
9 |
6/9 (66.7) |
| Lobular |
1 |
1/1 (100) |
|
Group III: gastrointestinal |
16 |
10/16 (62.5) |
| Stomach cancer |
3 |
2/3 (66.7) |
| Colorectal cancer |
7 |
4/7 (57.1) |
| Other |
6 |
4/6 (66.7) |
|
Group IV: hematological |
62 |
42/62 (67.7) |
| Acute myeloid leukemia |
7 |
4/7 (57.1) |
| Chronic myelogenous leukemia |
2 |
1/2 (50) |
| Hodgkin’s lymphoma |
5 |
4/5 (85.7) |
| Non-Hodgkin’s lymphoma |
13 |
11/13 (84.6) |
| Other lymphoma |
7 |
6/7 (85.7) |
| Multiple myeloma |
13 |
10/13 (77) |
| Idiopathic thrombocytopenia |
5 |
4/5 (76.9) |
| Myelodysplastic syndrome |
10 |
2/10 (20) |
|
Group V: urogenital cancers |
8 |
8/8 (100) |
| Ovarian cancer |
2 |
2/2 (100) |
| Testicular cancer |
2 |
2/2 (100) |
| Prostate cancer |
1 |
1/1 (100) |
| Urinary tract cancer |
3 |
3/3 (100) |
|
Group VI: CUP |
5 |
5/5 (100) |
| Group VII: other solid tumors | 13 | 13/13 (100) |